FLT3 Receptor Antagonists for Pain Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain disorders, particularly those involving hyperalgesia and inflammatory pain, have limited effectiveness due to the lack of investigation into the FLT3 receptor pathway, which plays a crucial role in pain regulation.
Innovation Solution
Development of FLT3 receptor antagonists and inhibitors of FLT3 receptor gene expression to block the biological activity associated with the FLT3 receptor, specifically targeting the receptor with small organic molecules, antibodies, or nucleic acids to prevent pain disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for pain disorders are used, then existing pain management approaches are maintained, but effectiveness is limited due to lack of investigation into FLT3 receptor pathway
Solution Approach 1:
The patent performs preliminary investigation and identification of the FLT3 receptor pathway's role in pain regulation before developing treatments. By pre-establishing the therapeutic potential of FLT3 antagonists through in vitro and in vivo studies, the patent creates a foundation for effective pain management that addresses the lack of prior investigation into this pathway
2Object-affected harmful factors
If FLT3 receptor antagonists are developed to block FLT3 receptor biological activity, then pain sensitivity is reduced and hyperalgesia is alleviated, but the complexity of the treatment approach increases
Solution Approach 1:
The patent extracts and isolates the specific FLT3 receptor pathway from the complex network of pain signaling mechanisms. By developing selective FLT3 receptor antagonists that specifically block this single pathway, the patent simplifies the treatment approach while effectively addressing pain sensitivity and hyperalgesia, rather than using broad-spectrum pain medications
3Object-affected harmful factors
If FLT3 receptor antagonists target the interaction between FLT3 receptor and its ligand, then thermal and mechanical hyperalgesia are alleviated, but the specificity of targeting required increases
Solution Approach 1:
The patent applies local quality by designing FLT3 receptor antagonists with high specificity for the FLT3 receptor binding site. The antagonists are engineered to interact precisely with the unique structural features of the FLT3 receptor and its ligand FL, ensuring selective blockade of this specific pathway while minimizing off-target effects on other receptor systems
Data Source
AI summary
The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.